Treatment of age-related macular degeneration: focus on ranibizumab

References

• AbugreenSMuldrewKAStevensonMR2003CNV subtype in first eyes predicts severity of ARM in fellow eyesBr J Ophthalmol873071112598444
   PubMed Web of Science ®Google Scholar
• AdamisAPMillerJWBernalMT1994Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathyAm J Ophthalmol118445507943121
   PubMed Web of Science ®Google Scholar
• AdamisAPShimaDTTolentinoMJ1996Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primateArch Ophthalmol11466718540853
   PubMed Web of Science ®Google Scholar
• AdamsGPWeinerLM2005Monoclonal antibody therapy of cancerNat Biotech23114757
   PubMed Web of Science ®Google Scholar
• AisenbreySLafautBASzurmanP2002Macular translocation with 360 degrees retinotomy for exudative age-related macular degenerationArch Ophthalmol120451911934318
   PubMedGoogle Scholar
• AisenbreySZiemssenFVolkerM2007Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2459418817186262
   PubMed Web of Science ®Google Scholar
• AkiyamaHMohamedaliKASilvaRLE2005Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric proteinMol Pharmacol6815435016150930
   PubMed Web of Science ®Google Scholar
• AriasLGarcia-ArumiJRamonJM2006Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized studyOphthalmology11322435016996600
   PubMed Web of Science ®Google Scholar
• AveryRLPieramiciDJRabenaMD2006Intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationOphthalmology1133637216458968
   PubMed Web of Science ®Google Scholar
• BashshurZFBazarbachiASchakalA2006Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degenerationAm J Ophthalmol1421916815245
   PubMed Web of Science ®Google Scholar
• BresslerNMArnoldJBenchabouneM2002Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes-TAP report No. 3Arch Ophthalmol12014435412427056
   PubMedGoogle Scholar
• BresslerNMBresslerSBHawkinsBSSubmacular Surgery Trials Pilot Study Investigators. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1Am J Ophthalmol13038740711024412
   PubMed Web of Science ®Google Scholar
• BresslerNMBresslerSBHaynesLA2005Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7Arch Ophthalmol1231283516157822
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsM2006Ranibizumab versus verteporfin for neovascular age-related macular degenerationN Eng J Med355143244
   PubMed Web of Science ®Google Scholar
• BrownMMBrownGCBrownH2007Value-based medicine and interventions for macular degenerationCurr Opin Ophthalmol1819420017435425
   PubMed Web of Science ®Google Scholar
• ChangTSBresslerNMFineJT2007Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trialArch Ophthalmol1251460917998507
   PubMed Web of Science ®Google Scholar
• ChenYWiesmannCFuhG1999Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigenJ Mol Biol2938658110543973
   PubMed Web of Science ®Google Scholar
• ChenCYWongTYHeriotWJ2007Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term studyAm J Ophthalmol1435101217317398
   PubMed Web of Science ®Google Scholar
• CostaRAJorgeRCalucciD2006Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation studyInvest Ophthalmol Vis Sci4745697817003454
   PubMed Web of Science ®Google Scholar
• EmersonMVLauerAKFlaxelCJ2007Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degenerationRetina274394417420695
   PubMed Web of Science ®Google Scholar
• ErgunEMaarNAnsari-ShahrezaeiS2006Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degenerationAm J Ophthalmol142101616815246
   PubMed Web of Science ®Google Scholar
• FeinerLBarrEEShuiYB2006Safety of intravitreal injection of bevacizumab in rabbit eyesRetina26882817031287
   PubMed Web of Science ®Google Scholar
• FerraraNDamicoLShamsN2006Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina268597017031284
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJ2003The biology of VEGF and its receptorsNat Med96697612778165
   PubMed Web of Science ®Google Scholar
• FingarVH1996Vascular effects of photodynamic therapyJ Clin Laser Med Surg1432389612199
   PubMedGoogle Scholar
• FujiiGYde JuanEJrPieramiciDJ2002Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence reportAm J Ophthalmol134697412095810
   PubMed Web of Science ®Google Scholar
• FungAELalwaniGARosenfeldPJ2007An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol1435668317386270
   PubMed Web of Science ®Google Scholar
• FungAERosenfeldPJReichelE2006The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBr J Ophthalmol901344916854824
   PubMed Web of Science ®Google Scholar
• GaudreaultJFeiDRusitJ2005Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administrationInvest Ophthalmol Vis Sci467263315671306
   PubMed Web of Science ®Google Scholar
• GeliskenFVoelkerMSchwabeR2007Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT)Graefes Arch Clin Exp OphthalmolJan 12 (Epub)
   Web of Science ®Google Scholar
• Genentech “Dear Health Care Provider” letter January 24, 2007; available at http://www.gene.com./gene/products/information/tgr/lucentis/index.jsp.
   Google Scholar
• GoffMJJohnsonRNMcDonaldHR2007Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degenerationRetina274323817420694
   PubMed Web of Science ®Google Scholar
• GragoudasESAdamisAPCunninghamET2004Pegaptanib for neovascular age-related macular degenerationN Engl J Med35128051615625332
   PubMed Web of Science ®Google Scholar
• GreenWRWilsonDJChoroidal neovascularization1986Ophthalmology931169762433662
   PubMed Web of Science ®Google Scholar
• GrossniklausHELingJXWallaceTM2002Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularizationMol Vis81192611979237
   PubMed Web of Science ®Google Scholar
• HeiduschkaPFietzHHofmeisterS20007. Penetration of bevacizumab through the retina after intravitreal injection in the monkeyInvest Ophthalmol Vis Sci48281423
   Web of Science ®Google Scholar
• HeierJSAntoszykANPavanPR2006bRanibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose studyOphthalmology113633642.e1-4
   PubMed Web of Science ®Google Scholar
• HeierJSBoyerDSCiullaTA2006aRanibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS StudyArch Ophthalmol12415321542 Erratum in: Arch Ophthalmol, 2007;125:138
   Google Scholar
• HeussenFMFawzyNFJoeresS2007Autologous translocation of the choroid and RPE in age-related macular degeneration: 1-year follow-up in 30 patients and recommendations for patient selectionEyeJul 20 (Epub ahead of print)
   Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyW2004Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Eng J Med350233542
   PubMed Web of Science ®Google Scholar
• HusainDKimIGauthierD2005Safety and efficacy of intravit-real injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkeyArch Ophthalmol1235091615824225
   PubMed Web of Science ®Google Scholar
• KaiserPKBlodiBAShapiroH2007Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular DegenerationOphthalmologyJul 11 (Epub ahead of print)
   Web of Science ®Google Scholar
• KleinRKleinBEKLintonKP1993The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking 1993Am J Epidemiol1371902008452123
   PubMed Web of Science ®Google Scholar
• KrzystolikMGAfshariMAAdamisAP2002Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragmentArch Ophthalmol1203384611879138
   PubMed Web of Science ®Google Scholar
• LazicRGabricN2007Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degenerationGraefes Arch Clin Exp Ophthalmol245687317111146
   PubMed Web of Science ®Google Scholar
• LeiJJiangAPeiD1998Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183Biochim Biophys Acta4434006
   Web of Science ®Google Scholar
• LeungDWCachianesGKuangWJ1989Vascular endothelial growth factor is a secreted angiogenic mitogenScience246130692479986
   PubMed Web of Science ®Google Scholar
• London New Drugs Group. May 2007. Ranibizumab, pegaptanib and bevacizumab for the treatment of age-related macular degeneration. APC/DTC Briefing.
   Google Scholar
• LukeMWargaMZiemssenF2006Effects of bevacizumab on retinal function in isolated vertebrate retinaBr J Ophthalmol9011788216754646
   PubMed Web of Science ®Google Scholar
• MacLarenREUppalGSBalagganKS2007Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degenerationOphthalmology1145617017324698
   PubMed Web of Science ®Google Scholar
• Macular photocoagulation study group1991Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trialsArch Ophthalmol1091109141714270
   PubMed Web of Science ®Google Scholar
• MaguireMComplications of Age-Related Macular Degeneration Prevention Trial Research Group2004Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT)Ophthalmology11113071615234130
   PubMed Web of Science ®Google Scholar
• MaturiRKBleauLAWilsonDL2006Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatmentRetina26270416508425
   PubMed Web of Science ®Google Scholar
• MichelsS2006Is intravitreal bevacizumab (Avastin) safe?Br J Ophthalmol901333417057166
   PubMed Web of Science ®Google Scholar
• MielerWF2006PIER: Year 1 FA/OCT Results in a Study of Ranibizumab (Lucentis™) for Choroidal Neovascularisation (CNV) due to Age related Macular Degeneration (AMD)Program and abstract of the 24th Annual American Society of Retina Specialists and 6th Annual European Vitreoretinal Society MeetingSeptember 9–13, 2006Cannes, France Abstract 507
   Google Scholar
• MordentiJThomsenKLickoV1999Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravit-real administration of a solution or a PLGA microsphere formulationToxicol Sci521016
   PubMed Web of Science ®Google Scholar
• MoshfeghiAARosenfeldPJPuliafitoCA2006Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twenty-four-week results of an uncontrolled open-label clinical studyOphthalmology11320021117027972
   PubMed Web of Science ®Google Scholar
• MruthyunjayaPStinnettSSTothCA2004Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degenerationOphthalmology11117152415350328
   PubMed Web of Science ®Google Scholar
• MullerYAChenYChristingerHW1998VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interfaceStructure61153679753694
   PubMed Web of Science ®Google Scholar
• OlsonMK2004Are novel drugs more risky for patients than less novel drugs?J Health Econ2311355815556240
   PubMed Web of Science ®Google Scholar
• PieramiciDJAveryRL2006Ranibizumab: treatment in patients with neovascular age-related macular degenerationExpert Opin Biol Ther612374517049020
   PubMed Web of Science ®Google Scholar
• PierceEAFoleyEDSmithLE1996Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurityArch Ophthalmol1141219288859081
   PubMedGoogle Scholar
• PrestaLGChenHO’ConnorSJ1997Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res57459399377574
   PubMed Web of Science ®Google Scholar
• RakicJMLambertVDevyL2003Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci4431869312824270
   PubMed Web of Science ®Google Scholar
• RafteryJCleggAJonesJ2007Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectivenessBr J Ophthalmol911244617431015
   PubMed Web of Science ®Google Scholar
• RichRMRosenfeldPJPuliafitoCA2006Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationRetina2649551116770255
   PubMed Web of Science ®Google Scholar
• RosenfeldPJ2006Intravitreal avastin: the low cost alternative to lucentis?Am J Ophthalmol142141316815262
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJS2006aRanibizumab for neovascular age-related macular degenerationN Eng J Med355141931
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeijerJS2006cSupplementary Appendix to Ranibizumab for neovascular age-related macular degenerationN Eng J Med355141931
   PubMed Web of Science ®Google Scholar
• RosenfeldPJHeierJSHantsbargerG2006bTolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degenerationOphthalmology11362332.e1
   PubMed Web of Science ®Google Scholar
• RosenfeldPJMoshfeghiAAPuliafitoCA2005aOptical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degenerationOphthalmic Surg Lasers Imaging3633135
   PubMed Web of Science ®Google Scholar
• RosenfeldPJSchwartzSDBlumenkranzMS2005bMaximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degenerationOphthalmology112104853
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUMichelsSBarbazettoI2002Photodynamic effects on choroidal neovascularization and physiological choroidInvest Ophthalmol Vis Sci438304111867605
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUMRichardGAugustinA2007Guidance for the treatment of neovascular age-related macular degenerationActa Ophthalmol Scand854869417655610
   PubMedGoogle Scholar
• Schmidt-ErfurthUSchlotzer-SchrehardUCursiefenC2003Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factorInvest Ophthalmol Vis Sci4444738014507895
   PubMed Web of Science ®Google Scholar
• SengerDRGalliSJDvorakAM1983Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluidScience21998356823562
   PubMed Web of Science ®Google Scholar
• ShaharJAveryRLHeilweilG2006Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)Retina26262916508424
   PubMed Web of Science ®Google Scholar
• SpaideRFLaudKFineHF2006Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degenerationRetina263839016603955
   PubMed Web of Science ®Google Scholar
• SpitzerMSWallenfels-ThiloBSierraA2006Antiproliferative and cytotoxic properties of bevacizumab on different ocular cellsBr J Ophthalmol9013162116723358
   PubMed Web of Science ®Google Scholar
• SpitzerMSYoeruekESierraA2007Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cellsGraefes Arch Clin Exp OphthalmolMar 9 (Epub ahead of print)
   Web of Science ®Google Scholar
• SteinbrookR2006The price of sight – ranibizumab, bevacizumab, and the treatment of macular degenerationN Engl J Med35514091217021315
   PubMed Web of Science ®Google Scholar
• StoneEM2006A very effective treatment for neovascular macular degenerationN Engl J Med3551493517021326
   PubMed Web of Science ®Google Scholar
• TakahashiHShibuyaM2005The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditionsClin Sci (Lond)1092274116104843
   PubMed Web of Science ®Google Scholar
• TakedaALColquittJLCleggAJ2007Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic reviewBr J Ophthalmol (Epub ahead of print; May 2 2007)
   Web of Science ®Google Scholar
• TatarOAdamAShinodaK2006Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapyAm J Ophthalmol1429510416815256
   PubMed Web of Science ®Google Scholar
• VirgiliGBiniA2000Laser photocoagulation for neovascular age-related macular degenerationCochrane Database Syst Rev8CD004763
   Google Scholar
• WellsJAMurthyRChibberR1996Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisationBr J Ophthalmol8036368703891
   PubMed Web of Science ®Google Scholar
• WormaldREvansJSmeethLHenshawK2005Photodynamic therapy for neovascular age-related macular degenerationCochrane Database Syst Rev19CD002030
   Google Scholar
• WuLMartinez-CastellanosMAQuiroz-MercadoH2007Twelvemonth safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES)Graefes Arch Clin Exp Ophthalmol Aug 3 [Epub ahead of print]
   Web of Science ®Google Scholar
• www.clinicaltrials.gov/show/NCT00331864.
   Google Scholar
• ZarbinMSzirthB2007Current treatment of age-related macular degenerationOptom Vis Sci845597217632299
   PubMed Web of Science ®Google Scholar
• ZiemssenFLukeMMessiasA2007Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patientsInt OphthalmolJuly 20 [Epub ahead of print]
   Google Scholar